ACT HPB: The Role of Y90 and Hepatic Artery Infusion (HAI) Chemotherapy in the Management of Unresectable Intrahepatic Cholangiocarcinoma

Saturday, March 12, 2022

11:30 AM – 12:00 PM CST

Location:Chantilly West

Participants should be aware of the following financial/non-financial relationships:

William Rilling, MD: BD/Bard (Individual(s) Involved: Self): Consultant; Boston Scientific (Individual(s) Involved: Self): Advisor or Review Panel member; Sirtex (Individual(s) Involved: Self): Consultant, Research Grant or Support; Terumo (Individual(s) Involved: Self): Consultant; Varian (Individual(s) Involved: Self): Consultant

Adel Kardosh, MD, PhD: Astellas Pharma Inc. (Individual(s) Involved: Self): Advisor or Review Panel member; Eisai Co., Ltd. (Individual(s) Involved: Self): Advisor or Review Panel member; Natera Inc (Individual(s) Involved: Self): Research Grant or Support

Y90 perspective 11:32 AM 11:42 AM Bill Rilling
HAI perspective 11:42 AM 11:52 AM Adel Kardosh

Presentations:

11:30 AM – 11:32 AM CST

Introductions
Presenter: William Rilling, MD – Medical College of Wisconsin
Presenter: Adel Kardosh, MD, PhD – Oregon Health and Science University
11:32 AM – 11:42 AM CST

Y90 Perspective
Presenter: William Rilling, MD – Medical College of Wisconsin
11:42 AM – 11:52 AM CST

HAI Perspective
Presenter: Adel Kardosh, MD, PhD – Oregon Health and Science University